MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Ítems similars

• Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
  per: Zhang, Zhe, et al.
  Publicat: (2019)
• EGFR/Met association regulates EGFR TKI resistance in breast cancer
  per: Mueller, Kelly L, et al.
  Publicat: (2010)
• Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
  per: Kanemura, Hiroaki, et al.
  Publicat: (2020)
• MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
  per: Presutti, Dario, et al.
  Publicat: (2015)
• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
  per: Wu, Shang-Gin, et al.
  Publicat: (2018)